DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more
DNA Link Inc (127120) - Total Liabilities
Latest total liabilities as of September 2025: ₩48.57 Billion KRW
Based on the latest financial reports, DNA Link Inc (127120) has total liabilities worth ₩48.57 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
DNA Link Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how DNA Link Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
DNA Link Inc Competitors by Total Liabilities
The table below lists competitors of DNA Link Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KATITAS CO., Ltd.
PINK:KTITF
|
USA | $37.61 Billion |
|
INVEX Controladora S.A.B. de C.V
MX:INVEXA
|
Mexico | MX$201.87 Billion |
|
Henan Thinker Automation
SHG:603508
|
China | CN¥309.15 Million |
|
Shaily Engineering Plastics Limited
NSE:SHAILY
|
India | ₹4.19 Billion |
|
Winner Information Technology Co Inc
SHE:300609
|
China | CN¥220.83 Million |
|
Grupo Posadas S.A.B. de C.V
MX:POSADASA
|
Mexico | MX$17.85 Billion |
|
Scientech Corp
TW:3583
|
Taiwan | NT$17.49 Billion |
|
Fuxin Dare Automotive Parts Co Ltd
SHE:300473
|
China | CN¥2.43 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down DNA Link Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DNA Link Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DNA Link Inc (2011–2024)
The table below shows the annual total liabilities of DNA Link Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩29.36 Billion | +135.23% |
| 2023-12-31 | ₩12.48 Billion | -20.09% |
| 2022-12-31 | ₩15.62 Billion | +89.40% |
| 2021-12-31 | ₩8.25 Billion | -40.42% |
| 2020-12-31 | ₩13.84 Billion | -14.77% |
| 2019-12-31 | ₩16.24 Billion | +5.02% |
| 2018-12-31 | ₩15.46 Billion | +996.65% |
| 2017-12-31 | ₩1.41 Billion | -94.14% |
| 2016-12-31 | ₩24.04 Billion | +11.69% |
| 2015-12-31 | ₩21.53 Billion | +68.92% |
| 2014-12-31 | ₩12.74 Billion | +3.34% |
| 2012-12-31 | ₩12.33 Billion | +37.43% |
| 2011-12-31 | ₩8.97 Billion | -- |